Pyxis Oncology, Inc. (NASDAQ: PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.33, delivering a surprise of 32.65%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Pyxis Oncology, which belongs to the Zacks Medical - Drugs industry, posted revenues of $16.15 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 279.91%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Pyxis Oncology shares have added about 138.3% since ...